StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Thursday morning. The brokerage issued a sell rating on the biotechnology company's stock.
Several other research firms also recently issued reports on GNCA. Stifel Nicolaus downgraded Genocea Biosciences from a buy rating to a hold rating in a report on Friday, April 29th. HC Wainwright downgraded Genocea Biosciences from a buy rating to a neutral rating in a report on Friday, April 29th.
Get
Genocea Biosciences alerts:
Genocea Biosciences Price Performance
GNCA stock opened at $0.01 on Thursday. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $640,200.60, a PE ratio of -0.02 and a beta of 2.00. Genocea Biosciences has a 12-month low of $0.01 and a 12-month high of $2.20. The business's fifty day moving average price is $0.01 and its 200 day moving average price is $0.42.
Institutional Investors Weigh In On Genocea Biosciences
A hedge fund recently bought a new stake in Genocea Biosciences stock. Acadian Asset Management LLC purchased a new position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 21,741 shares of the biotechnology company's stock, valued at approximately $25,000. Institutional investors and hedge funds own 59.25% of the company's stock.
About Genocea Biosciences
(Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Featured Stories
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Why Trading Volume is Unusually High on These 3 Stocks
- Can NetApp Resume Its Rally After Strong Earnings Guidance?
- Three Reasons Why Medtronic Stock can be a Recession Winner
- Rivian Rising to the Challenge
- 3 Deflation Enablers Stocks that Can Thrive in a Recession
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Thursday morning. The brokerage issued a sell rating on the biotechnology company's stock.
斯托克新闻网在周四上午发布的一份报告中开始报道Genocea Biosciences(纳斯达克：GNCA-GET评级)的股票。该经纪公司对这家生物技术公司的股票发布了卖出评级。
Several other research firms also recently issued reports on GNCA. Stifel Nicolaus downgraded Genocea Biosciences from a buy rating to a hold rating in a report on Friday, April 29th. HC Wainwright downgraded Genocea Biosciences from a buy rating to a neutral rating in a report on Friday, April 29th.
其他几家研究公司最近也发布了关于GNCA的报告。Stifel Nicolaus在4月29日星期五的一份报告中将Genocea Biosciences的评级从买入下调至持有。在4月29日星期五的一份报告中，HC Wainwright将Genocea Biosciences的评级从买入下调至中性。
Get
Genocea Biosciences
alerts:
Genocea Biosciences Price Performance
GNCA stock opened at $0.01 on Thursday. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $640,200.60, a PE ratio of -0.02 and a beta of 2.00. Genocea Biosciences has a 12-month low of $0.01 and a 12-month high of $2.20. The business's fifty day moving average price is $0.01 and its 200 day moving average price is $0.42.
周四，GNCA的股票开盘报0.01美元。该公司的流动比率为1.35，速动比率为1.35，债务权益比率为0.24。该公司市值为640,200.60美元，市盈率为-0.02，贝塔系数为2.00。Genocea Biosciences的12个月低点为0.01美元，12个月高位为2.20美元。该业务的50日移动均线价格为0.01美元，其200日移动均线价格为0.42美元。
Institutional Investors Weigh In On Genocea Biosciences
A hedge fund recently bought a new stake in Genocea Biosciences stock. Acadian Asset Management LLC purchased a new position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 21,741 shares of the biotechnology company's stock, valued at approximately $25,000. Institutional investors and hedge funds own 59.25% of the company's stock.
一家对冲基金最近购买了Genocea Biosciences股票的新股份。根据Acadian Asset Management LLC在最近提交给美国证券交易委员会的13F文件中显示，该公司在第四季度购买了Genocea Biosciences，Inc.(纳斯达克代码：GNCA-GET Rating)的新股票头寸。该机构投资者购买了21,741股生物技术公司的股票，价值约25,000美元。机构投资者和对冲基金持有该公司59.25%的股票。
About Genocea Biosciences
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea Biosciences，Inc.是一家生物制药公司，发现和开发新型癌症免疫疗法。该公司使用其专有的发现平台ATLAS，该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。
Featured Stories
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Why Trading Volume is Unusually High on These 3 Stocks
- Can NetApp Resume Its Rally After Strong Earnings Guidance?
- Three Reasons Why Medtronic Stock can be a Recession Winner
- Rivian Rising to the Challenge
- 3 Deflation Enablers Stocks that Can Thrive in a Recession
- 免费获取StockNews.com关于基因组生物科学的研究报告(GNCA)
- 这三只股票的成交量为何异常高
- 在强劲的盈利指引之后，NetApp能否恢复涨势？
- 美敦力股票可以成为经济衰退赢家的三个原因
- Rivian迎接挑战
- 3通缩使能在经济衰退中蓬勃发展的股票
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
